L-Asparaginase-induced coagulopathy during therapy of acute lymphocytic leukemia.
L-Asparaginase-induced coagulation abnormalities were observed in all patients receivng this drug. All patients studied demonstrated low factor IX and fibrinogen levels and most (75%) had low levels of factor XI. Disturbances in other factors were much less frequent. Despite the presence of markedly abnormal coagulation studies, clinical bleeding was not observed.
D000293:Adolescent; D000347:Afibrinogenemia / Q000139:chemically induced; D001215:Asparaginase / Q000009:adverse effects*; D001778:Blood Coagulation Disorders / Q000139:chemically induced*; D002648:Child; D002675:Child, Preschool; D005173:Factor XI Deficiency / Q000139:chemically induced; D005260:Female; D002836:Hemophilia B / Q000139:chemically induced; D006801:Humans; D007223:Infant; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008297:Male
D001215:Asparaginase